These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 33746969)
21. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Cho SF; Anderson KC; Tai YT Front Immunol; 2018; 9():1821. PubMed ID: 30147690 [TBL] [Abstract][Full Text] [Related]
22. Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model. Vo MC; Yang S; Jung SH; Chu TH; Lee HJ; Lakshmi TJ; Park HS; Kim HJ; Lee JJ Front Immunol; 2018; 9():1798. PubMed ID: 30123221 [TBL] [Abstract][Full Text] [Related]
23. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564 [TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928 [TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Raza S; Safyan RA; Lentzsch S Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976 [TBL] [Abstract][Full Text] [Related]
35. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma. Kim GW; Yoo J; Won HR; Yeon SK; Lee SW; Lee DH; Jeon YH; Kwon SH Leuk Res; 2020 Aug; 95():106398. PubMed ID: 32512378 [TBL] [Abstract][Full Text] [Related]
36. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Chang X; Zhu Y; Shi C; Stewart AK Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):240-53. PubMed ID: 24374776 [TBL] [Abstract][Full Text] [Related]
37. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma. Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433 [TBL] [Abstract][Full Text] [Related]
38. Monoclonal antibodies as an addition to current myeloma therapy strategies. Jullien M; Touzeau C; Moreau P Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750 [TBL] [Abstract][Full Text] [Related]
39. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Paiva B; Mateos MV; Sanchez-Abarca LI; Puig N; Vidriales MB; López-Corral L; Corchete LA; Hernandez MT; Bargay J; de Arriba F; de la Rubia J; Teruel AI; Giraldo P; Rosiñol L; Prosper F; Oriol A; Hernández J; Esteves G; Lahuerta JJ; Bladé J; Perez-Simon JA; San Miguel JF; Blood; 2016 Mar; 127(9):1151-62. PubMed ID: 26668134 [TBL] [Abstract][Full Text] [Related]
40. Immunomodulatory drugs in multiple myeloma. Zangari M; Elice F; Tricot G Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]